Clinical trials: Immunocompromised Patients
SARS CoV 2 Infection, COVID-19
Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations
The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182).
- Trial name
- COVICO (NCT05667597)
- Testing
- Humoral immunity
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Maria Goossens
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
Acute Respiratory Failure, Immunocompromised Host
Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients
In immunocompromised patients, Acute Respiratory Failure (ARF) is associated with a high case-fatality, particularly when invasive Mechanical Ventilation (MV) is required.
- Conditions
- Acute Respiratory Failure, Immunocompromised Host, High Flow Oxygen Cannula
- Trial name
- RESPIR-OH (NCT02424773)
- Testing
- High Flow Nasal Canula (HFNC), Venturi mask, Oxygen
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
EBV Viremia
Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients
The NeuMoDx EBV Quant Assay 2.0 study is a multi-center, observational clinical investigation designed to evaluate the performance of the NeuMoDx EBV Quant Assay 2.0 in quantifying Epstein-Barr virus (EBV) DNA levels in plasma…
- Trial name
- NCT06681025
- Testing
- NeuMoDx EBV Quant 2.0 Assay
- Where
- United Kingdom
- Volunteers
- 1,070 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Inflammatory Bowel Disease (IBD), Immunosuppressed or Non-Immunosuppressed
Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
The purpose of this study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) on immunosuppressive therapy with IBD patients on aminosalicylates and healthy historical…
- Conditions
- Inflammatory Bowel Disease (IBD), Immunosuppressed or Non-Immunosuppressed, Influenza Vaccine, Antibody Titers
- Trial name
- NCT00542776
- Testing
- blood draw
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Boston Children's Hospital
Parainfluenza Infection
DAS181 in Patients With Parainfluenza
Background: Parainfluenza is a virus that can cause infections in people. Most people infected with this virus have mild symptoms including fever, cough, red eyes, or runny nose (a common cold).
- Trial name
- NCT01441024
- Testing
- DAS181
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immuno-modulation, Immuno-suppression
Analysis of the Specificity and Persistence of Nasal Immune Responses to Respiratory Viral Antigens in Immunocompromised and Healthy Cohorts
The goal of this observational study is to characterize nasal mucosal immunity to respiratory viruses, such as SARS-CoV-2, in immunocompromised individuals and healthy volunteers.
- Conditions
- Immuno-modulation, Immuno-suppression, Immunocompromised Patients, Healthy Subjects
- Trial name
- NCT07295535
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
HIV Seropositivity, Immunodeficiency
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional…
- Conditions
- HIV Seropositivity, Immunodeficiency, Vaccination Reaction, Covid19
- Trial name
- NCT05672654
- Testing
- Blood draw
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Covid19
PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V
COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or to reduce the severity of illness if given as prophylaxis.
- Trial name
- PROTECT-V (NCT04870333)
- Testing
- Niclosamide, Ciclesonide, Sotrovimab
- Where
- 45 sites in United Kingdom
- Volunteers
- 2,240 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Acquired Immune Deficiency Syndrome Virus
Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir
There are few randomized clinical trials in advanced HIV patients. This is a multicenter, randomized, open clinical trial, comparing 2 parallel groups, to compare the immunological reconstitution and the virological efficacy and…
- Trial name
- NCT02337322
- Testing
- Dolutegravir, Darunavir/r
- Where
- Spain
- Volunteers
- 104 people
- Sponsor
- Juan A. Arnaiz
Diarrhea Caused by Drug, Dysbiosis
Monitoring the Effects of Probiotic Supplementation in Immunocompromised Kidney Transplanted Subjects
In order to protect their new renal graft, post-transplant patients follow a rigorous immunosuppressive therapy combined with prophylactic antibiotic treatment.
- Trial name
- NCT05102461
- Testing
- Florajen Digestion Supplementation
- Where
- United States
- Sponsor
- State University of New York - Upstate Medical University
Pneumococcal Infection, ANCA-associated Vasculitis
Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis
Descriptive study of the residual anti-pneumococcal immunity in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) who have previously gone through pneumococcal immunization.
- Trial name
- NCT02463539
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Immunocompromised Patient, Aspergillosis
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
This is a trial to determine whether giving a patient a tailored dose of voriconazole is safe and effective.
- Conditions
- Immunocompromised Patient, Aspergillosis, Fusarium
- Trial name
- PIVOTAL (NCT01887457)
- Testing
- VFEND
- Where
- United Kingdom
- Volunteers
- 33 people
- Sponsor
- Brynn Chappell
Hematologic Diseases, Sepsis
Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis
A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis.
- Trial name
- SEPTIFAST (NCT00561639)
- Where
- France
- Volunteers
- 76 people
- Sponsor
- University Hospital, Grenoble
Influenza
A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants
This 2 arm study will evaluate the efficacy and safety of oseltamivir in the seasonal prophylaxis of influenza in immunocompromised participants (as represented by transplant recipients).
- Trial name
- NCT00412737
- Testing
- Oseltamivir
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 477 people
- Sponsor
- Hoffmann-La Roche
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
Lower Respiratory Tract Infection, Parainfluenza
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
- Conditions
- Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
- Trial name
- NCT03808922
- Testing
- DAS181, DAS181 COVID-19, DAS181 OL
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 274 people
- Sponsor
- Ansun Biopharma, Inc.
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
COVID-19, Immunocompromised Host
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
This prospective cohort of patients, receiving pre exposure prophylaxis by Anti-SARS-CoV-2 Monoclonal Antibodies, is designed to evaluate the treatment protection against SARS-CoV-2 variants of concerns
- Trial name
- PRECOVIM (NCT05216588)
- Where
- France
- Volunteers
- 149 people
- Sponsor
- ANRS, Emerging Infectious Diseases